Oncology Pipeline

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

PI3Kα Inhibitor

LOXO-783

Type of Alteration(s)

Point Mutation

Alteration(s) of Interest

PIK3CA H1047R

Methodology

Key Considerations

Sanger Sequencing

Can detect all possible PIK3CA mutations within an exon
Detection may require higher tumor content than PCR-based assays

PCR-Based

Will detect selected mutations but may miss novel PIK3CA alterations

NGS (Tissue)

Should have full coverage of Exon 20

NGS (cfDNA)

Useful when tissue biopsy sample is limited/unavailable
Higher false negative rate than tissue-based NGS testing

Single base extension/MassArray

Will detect selected mutations but may miss novel PIK3CA alterations

References

1. Samuels Y, et al. Science. 2004;304(5670):554.

Check Clinical Trials information to see if patient qualifies

Need additional information or have a question:

Medical Science Liaison Request

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.